Scroll Top
Unfolding The Next Generation Of Allosteric Small Molecule Therapies To Meet Patient Needs
Combining physics-based methods with artificial intelligence, Gain is developing best-in-class small molecules for disorders with high unmet medical need.
Lead Program

Gain’s lead drug candidate GT-02287 is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. GT-02287 is currently being evaluated in a Phase I clinical study.

OUR DRUG DISCOVERY PLATFORM MAGELLAN™

By leveraging AI-supported 3D structural biology and supercomputer-powered proprietary physics-based models, Gain’s Magellan™ platform is able to identify novel allosteric binding sites on disease-implicated proteins and exploit their untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.

ALLOSTERIC PROTEIN REGULATION

Our next generation allosteric small molecule therapeutics can modulate a protein to restore or disrupt function, not just through inhibition or activation, but also through stabilization, destabilization and degradation, based on disease pathology.

PRESS RELEASES
Clear Filters

BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Partnership to investigate Gain’s structurally targeted allosteric regulator candidates (STARs) in cellular models of Gaucher disease and Parkinson’s disease November 30, 2020 09:40 ET | …

Read more

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models …

Read more

Corporate Presentation
August 2024
Corporate Presentation
Corporate Presentation
August 2024
Corporate Presentation